GSK press releases Follow Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma Sixth regulatory approval for Blenrep combinations with applications under review in all major markets https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combinations-approved-in-eu-for-treatment-of-relapsedrefractory-multiple-myeloma/ gsk.com
